Soterios Pharma Announces Phase 2 Results for Alopecia Areata Treatment STS-01

Soterios Pharma, a biopharmaceutical company based in the UK, has announced promising topline results from their Phase 2 study of STS-01, a topical treatment for mild-to-moderate alopecia areata (AA). 

What is STS-01?

STS-01 is a topical treatment for alopecia areata. It is a cytokine-targeting agent that modulates the inflammatory response and T-cell proliferation by disrupting signaling pathways. We don’t know anything else about the treatment’s mechanism of action.

Study Results

158 participants with mild or moderate alopecia received one of four doses of STS-01 ranging from 0.25% to 2% or placebo applied over 24 weeks. 

• ~76% of the 1% dose cohort met the primary endpoint of a greater than 30% improvement in the severity of alopecia as measured by the Severity of Alopecia Tool (SALT) score.
• 18% and 27% of the 1% and 2% dose cohorts, respectively, experienced complete hair regrowth, compared to 3% of the placebo group.
• Sorterios did not provide any further details about the other cohorts.
• In regards to safety, STS-01 was found to be well tolerated with no major adverse events. 

Reflections

Soterios aims for STS-01 to become the first approved therapy for mild-to-moderate alopecia areata. Currently approved therapies, such as Olumiant and Ritlecitinib, are approved only for severe alopecia areata. We look forward to seeing where further studies take Sorterios Pharma and STS-01.